PL2203433T3 - 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy - Google Patents

5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy

Info

Publication number
PL2203433T3
PL2203433T3 PL08832210T PL08832210T PL2203433T3 PL 2203433 T3 PL2203433 T3 PL 2203433T3 PL 08832210 T PL08832210 T PL 08832210T PL 08832210 T PL08832210 T PL 08832210T PL 2203433 T3 PL2203433 T3 PL 2203433T3
Authority
PL
Poland
Prior art keywords
oxoethoxy
thiazolidine
dione
methoxyphenyl
benzyl
Prior art date
Application number
PL08832210T
Other languages
English (en)
Polish (pl)
Inventor
Gerard R Colca
Robert C Gadwood
Tim Parker
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of PL2203433T3 publication Critical patent/PL2203433T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08832210T 2007-09-14 2008-09-15 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy PL2203433T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97263907P 2007-09-14 2007-09-14
EP08832210A EP2203433B1 (en) 2007-09-14 2008-09-15 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
PCT/US2008/010723 WO2009038681A1 (en) 2007-09-14 2008-09-15 Thiazolidinedione analogues for the treatment of hypertension

Publications (1)

Publication Number Publication Date
PL2203433T3 true PL2203433T3 (pl) 2013-04-30

Family

ID=40239575

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08832210T PL2203433T3 (pl) 2007-09-14 2008-09-15 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy

Country Status (15)

Country Link
US (1) US8067450B2 (https=)
EP (1) EP2203433B1 (https=)
JP (1) JP5371988B2 (https=)
KR (1) KR101537830B1 (https=)
CN (1) CN101848901B (https=)
AU (1) AU2008301905B2 (https=)
BR (1) BRPI0817096B8 (https=)
CA (1) CA2699289C (https=)
ES (1) ES2398313T3 (https=)
IL (1) IL204440A (https=)
MX (1) MX2010002820A (https=)
NZ (2) NZ597381A (https=)
PL (1) PL2203433T3 (https=)
RU (1) RU2486179C2 (https=)
WO (1) WO2009038681A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109037A2 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
UA96441C2 (ru) 2006-03-16 2011-11-10 Метаболик Солюшнз Девелопмент Компани Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
KR101537830B1 (ko) 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 고혈압 치료용 티아졸리딘디온 유사체
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
WO2011084459A1 (en) * 2009-12-15 2011-07-14 Metabolic Solutions Development Company Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
JP2013514369A (ja) * 2009-12-15 2013-04-25 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 糖尿病および他の代謝性疾患を処置するための、ｐｐａｒ温存チアゾリジンジオンおよび組み合わせ物
ES2617704T3 (es) * 2009-12-15 2017-06-19 Octeta Therapeutics, Llc Tiazolidindionas ahorradoras de PPAR y combinaciones para el tratamiento de enfermedades neurodegenerativas
RU2564661C2 (ru) 2009-12-15 2015-10-10 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MX2012012092A (es) * 2010-04-19 2012-12-17 Metabolic Solutions Dev Co Llc Sintesis novedosa para compuestos de tiazolidinadiona.
AU2011242844A1 (en) * 2010-04-21 2012-11-01 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2807815C (en) * 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
KR101988203B1 (ko) * 2010-08-10 2019-06-11 씨리우스 테라퓨틱스, 엘엘씨 티아졸리딘디온 화합물의 신규한 합성법
WO2012109495A1 (en) * 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
WO2015013187A1 (en) 2013-07-22 2015-01-29 Metabolic Solutions Development Co., Llc Ppar-sparing compounds for the treatment of metabolic diseases
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
WO2019154958A1 (en) 2018-02-08 2019-08-15 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
CA2106967C (en) 1991-04-11 2003-12-09 Takashi Sohda Thiazolidinedione derivatives, production and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
NO305987B1 (no) * 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
WO2000066102A2 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
IL147308A0 (en) 1999-06-30 2002-08-14 Tularik Inc Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US7009057B2 (en) 2001-04-26 2006-03-07 Zentiva A.S. Method for obtaining pioglitazone as an antidiabetic agent
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
DE60316152D1 (de) 2002-07-16 2007-10-18 Cadila Healthcare Ltd Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
US20060177444A1 (en) * 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
JP2005015477A (ja) * 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20070078170A1 (en) 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
KR100840465B1 (ko) 2004-09-28 2008-06-20 오츠카 세이야쿠 가부시키가이샤 카르보스티릴 화합물
UA96441C2 (ru) 2006-03-16 2011-11-10 Метаболик Солюшнз Девелопмент Компани Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
CN101448500A (zh) 2006-03-16 2009-06-03 新陈代谢解决方案开发公司 噻唑烷二酮类似物和糖皮质激素激动剂的组合疗法
WO2007109037A2 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
KR101537830B1 (ko) 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 고혈압 치료용 티아졸리딘디온 유사체
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues

Also Published As

Publication number Publication date
US8067450B2 (en) 2011-11-29
JP5371988B2 (ja) 2013-12-18
WO2009038681A1 (en) 2009-03-26
NZ583889A (en) 2012-01-12
NZ597381A (en) 2013-03-28
ES2398313T3 (es) 2013-03-15
AU2008301905A1 (en) 2009-03-26
AU2008301905B2 (en) 2013-06-27
CN101848901B (zh) 2012-11-21
EP2203433A1 (en) 2010-07-07
CA2699289A1 (en) 2009-03-26
KR20100075915A (ko) 2010-07-05
IL204440A (en) 2013-05-30
MX2010002820A (es) 2010-04-01
CA2699289C (en) 2016-01-19
HK1146484A1 (en) 2011-06-10
BRPI0817096A2 (pt) 2017-05-02
BRPI0817096A8 (pt) 2017-10-10
EP2203433B1 (en) 2012-10-31
KR101537830B1 (ko) 2015-07-17
JP2010539171A (ja) 2010-12-16
BRPI0817096B1 (pt) 2020-11-10
RU2010114727A (ru) 2011-10-20
CN101848901A (zh) 2010-09-29
RU2486179C2 (ru) 2013-06-27
US20100222399A1 (en) 2010-09-02
BRPI0817096B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PL2203433T3 (pl) 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy
HRP20180667T1 (hr) Protutijelo agonista kloto-beta za uporabu u liječenju dijabetesa ili otpornosti na inzulin
BRPI0814294A2 (pt) Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
GB2454555B (en) Alkoxy compounds for disease treatment
AP2010005180A0 (en) 5-substituted 2-(alkoxymethyl)furans
ATE516272T1 (de) 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
BRPI0922642A2 (pt) "formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo"
PT2947072T (pt) 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
IL209018A0 (en) Benzene sulfonamide thiazole and oxazole compounds
IL236883A0 (en) Intermediate compounds for the preparation of (1-(s))-n-(s-cyclohexyl-2-{(4)-2-(s-(fluoro-benzoyl)-thiazol-2-yl]pyrrolidine-1-yl}-2 -oxo-ethyl)-2-methylamino-propionamide
LT3228320T (lt) Insulino ir glp-1 agonisto derinys
BRPI0819595A2 (pt) Derivados quirais de 2-(benzilsulfinil)-tiazol e derivados de 2-[(1h-pirazol-4-ilmetil)sulfinil]-tiazol, processos para a sua peparação, bem como seu uso como herbicidas e reguladores do crescimento de plantas.
ZA201004239B (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
PL2358709T3 (pl) Grzybobójcze związki heterocykliczne
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
IL195511A0 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]
BR112013006336A2 (pt) (r)-(e)-2(4-(2-(5-(1-(3,5-dicloro piridin-4-il) etóxi)-1h-indazol-3-il)vinil-1-h-pirazol-1-il) etanol cristalino
IL200956A (en) 1– [2– (2,4 – dimethylphenylsulfonyl) –phenyl] piperazine for the treatment of pain
AP2010005364A0 (en) Novel heterocyclic compounds.
IL207854A0 (en) Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol
IL194549A0 (en) 2-(pyridin-2-yl)-pyrimidines for use as fungicides
SI2632921T1 (sl) Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj
IL200403A0 (en) Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide
PL2420233T3 (pl) Antagoniści receptora angiotensyny II do leczenia cukrzycy u kotów
IL195862A0 (en) 6-(heterocycle-substituted benzyl)-4-oxoquinoline compounds